Body-Made CAR-T cells take on Hard-to-Treat myeloma

NCT ID NCT07539233

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new gene therapy called QI-019B for people with multiple myeloma that has returned or not responded to at least two prior treatments. The therapy works by creating cancer-fighting CAR-T cells directly inside the patient's body. The study will enroll 24 participants to check safety and see if the treatment shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QI-019B (a gene therapy that creates CAR-T cells inside the body)
What this could lead to: If it works, this could offer a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early, small trial (24 people) focused on safety. The treatment may not work, and there are risks like severe immune reactions (cytokine release syndrome) and nerve problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA (MM)

Contacts and locations

Locations

Institute of Hematology & Blood Diseases Hospital

Tianjin, Tianjin Municipality, 300000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.